Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents

Human Immunology

Volumn 70, Issue 3, 2009, Pages 146-150

  Levitsky, Josh ^a   Miller, Joshua ^a,b   Wang, Edward ^a   Rosen, Anne ^a   Flaa, Cathy ^a   Abecassis, Michael ^a   Mathew, James ^a   Tambur, Anat ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Dendritic cells; Immunophenotyping; Immunosuppression; Liver transplantation; Regulatory T cells

Indexed keywords

ALEMTUZUMAB; CD4 ANTIGEN; CYCLOSPORIN; HLA G ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; LIVER GRAFT REJECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RECIPIENT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CELL SEPARATION; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TACROLIMUS;

EID: 61349091633     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2008.12.008     Document Type: Article

References (37)

1. Takatsuki M., Uemoto, Inomata Y., Egawa H., Kiuchi T., Fujita S., et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 72 (2001) 449-454
2. Tisone G., Orlando G., Cardillo A., Palmieri G., Manzia T.M., Baiocchi L., et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 44 (2006) 702-709
3. Girlanda R., Rela M., Williams R., O'Grady J.G., and Heaton N.D. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 37 (2005) 1708-1709
4. Hurwitz M., Desai D.M., Cox K.L., Berquist W.E., Esquivel C.O., and Millan M.T. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant 8 (2004) 267-272
5. Yokoi A., Nishimura E., Ogura Y., Fujimoto Y., Kasahara M., Kaihara S., et al. Complete withdrawal of immunosuppression in living donor liver transplantation. Transplant Proc 34 (2002) 1521
6. Lerut J., and Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 6 (2006) 1774-1780
7. Mazariegos G.V., Reyes J., Marino I., Flynn B., Fung J.J., and Starzl T.E. Risks and benefits of weaning immunosuppression in liver transplant recipients: Long-term follow-up. Transplant Proc 29 (1997) 1174-1177
8. Mazariegos G.V., Reyes J., Marino I.R., Demetris A.J., Flynn B., Irish W., et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 63 (1997) 243-249
9. Donckier V., Troisi R., Le Moine A., Toungouz M., Ricciardi S., Colle I., et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl 12 (2006) 1523-1528
10. Li Y., Koshiba T., Yoshizawa A., Yonekawa Y., Masuda K., Ito A., et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 4 (2004) 2118-2125
11. Martínez-Llordella M., Lozano J.J., Puig-Pey I., Orlando G., Tisone G., Lerut J., et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 118 (2008) 2845-2857
12. Devlin J., Doherty D., Thomson L., Wong T., Donaldson P., Portmann B., and Williams R. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 27 (1998) 926-933
13. Mazariegos G.V., Zahorchak A.F., Reyes J., Ostrowski L., Flynn B., Zeevi A., and Thomson A.W. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 3 (2003) 689-696
14. Wong T., Nouri-Aria K.T., Devlin J., Portmann B., and Williams R. Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology 28 (1998) 443-449
15. Le Rond S., Azéma C., Krawice-Radanne I., Durrbach A., Guettier C., Carosella E.D., and Rouas-Freiss N. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells. J Immunol 176 (2006) 3266-3276
16. Onishi Y., Fehervari Z., Yamaguchi T., and Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 105 (2008) 10113-10118
17. Brandenburg S., Takahashi T., de la Rosa M., Janke M., Karsten G., Muzzulini T., et al. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol 38 (2008) 1643-1653
18. Woltman A.M., De Fiijter J.W., Kamerling S.W., et al. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol 30 (2000) 1807
19. Szabo G., Gavala C., and Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Invest Med 49 (2001) 442
20. Coenen J.J., Koenen H.J., van Rijssen E., Hilbrands L.B., and Joosten I. Sirolimus, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 107 (2006) 1018-1023
21. Battaglia M., Stabilini A., and Roncarolo M.G. Sirolimus selectively expands the CD4+CD25+ regulatory T cells. Blood 105 (2005) 4743-4748
22. El Essaway B., Gao W., Liu P., et al. Sirolimus, not cyclosporine induces regulatory CD8+FOXP3+ cells, Abstract #40, World Transplant Congress (2006)
23. Battaglia M., Stabilini A., Draghici E., et al. Sirolimus and IL-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 55 (2006) 40-49
24. Mehling A., Grabbe S., Voskort M., et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 165 (2000) 2374-2381
25. Gregori S., Casorati M., Amuchastegui S., et al. Regulatory T cells induced by 1α, 25-Dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immun 167 (2001) 1945-1953
26. Nilolaeva N., Bemelman F.J., Yong S.L., et al. Sirolimus does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation 81 (2006) 445-454
27. Pascual J., Bloom D., Torrealba J., Brahmbhatt R., Chang Z., Sollinger H.W., and Knechtle S.J. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant 8 (2008) 1529-1536
28. Bloom D.D., Chang Z., Fechner J.H., Dar W., Polster S.P., Pascual J., et al. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 8 (2008) 793-802
29. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203 (2006) 1701-1711
30. Wertheimer A.M., Bakke A., and Rosen H.R. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology 40 (2004) 335-345
31. Mathew J.M., Vallone T., DeFaria W., Kato T., Alvarez S., Carreno M., et al. Relative resistance of activated T cells and NK cells to Alemtuzumab (Campath-1H) used in clinical transplantation. Hum Immunol 65 Suppl 1 (2004) S5
32. Watanabe T., Masuyama J., Sohma Y., Inazawa H., Horie K., Kojima K., et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 120 (2006) 247-259
33. Abe M., and Thomson A.W. Influence of immunosuppressive drugs on dendritic cells. Transpl Immunol 11 (2003) 357-365
34. Monti P., Mercalli A., Leone B.E., Valerio D.C., Allavena P., and Piemonti L. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 75 (2003) 137-145
35. Turnquist H.R., Raimondi G., Zahorchak A.F., Fischer R.T., Wang Z., and Thomson A.W. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 178 (2007) 7018-7031
36. Mazariegos G.V., Zahorchak A.F., Reyes J., Chapman H., Zeevi A., and Thomson A.W. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 5 (2005) 314-322
37. Crispim J.C., Duarte R.A., Soares C.P., Costa R., Silva J.S., Mendes-Júnior C.T., et al. Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transpl Immunol 18 (2008) 361-367